VEGFA and macular degeneration: In the current study, we aimed to explore the functional roles of VEGF in 4- to 5-month-old 5×FAD mice by specifically antagonizing VEGF function with systematic administration of bevacizumab, a humanized monoclonal antibody against VEGF and the most clinically advanced antiangiogenic agent used as the first-line treatment for cancer and macular degeneration [34], which prevents VEGF binding to its receptors.